Journal article
Research and standardization in Alzheimer's trials: Reaching international consensus
MC Carrillo, CC Rowe, C Szoeke, CL Masters, D Ames, T O'Meara, SL Macaulay, A Milner, KA Ellis, P Maruff, SR Rainey-Smith, RN Martins, LJ Bain, RJ Head
Alzheimer S and Dementia | Published : 2013
Abstract
Alzheimer's disease (AD) is an epidemic facing the entire world. Increased knowledge gained during the past 25 years indicates that AD falls along a clinical and neuropathological spectrum represented as a continuum that extends from preclinical disease in which there are no symptoms, through early symptomatic phases, and finally to AD dementia. The Alzheimer's research community recognizes that imaging, body fluids, and cognitive biomarkers contribute to enhanced diagnostic confidence for AD. There has also been emerging consensus regarding the use of AD biomarkers in clinical trials. The use of biomarkers in clinical trials and practice is hampered by the lack of standardization. In respon..
View full abstractGrants
Funding Acknowledgements
The authors thank the secretariat of the meeting and Lisa Osborne, Marion Thompson, Meredith McNeil, Kathy Lucas, Clare Faux, and Trisha Wooding. The meeting was supported, in part, by a grant to support AIBL's research from the Science and Industry Endowment Fund (www.sief.org.au), Alzheimer's Association, Foundation for the National Institutes for Health, GE Healthcare, and Janssen Research and Development.